Cardiac amyloidosis

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Cardiac amyloidosis | |
|---|---|
| Synonyms | Stiff heart syndrome |
| Pronounce | N/A |
| Specialty | Cardiology |
| Symptoms | Heart failure, arrhythmia, syncope, peripheral edema |
| Complications | Heart failure, sudden cardiac death |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Deposition of amyloid proteins in the heart |
| Risks | Family history, multiple myeloma, chronic inflammatory conditions |
| Diagnosis | Echocardiography, cardiac MRI, endomyocardial biopsy |
| Differential diagnosis | Hypertrophic cardiomyopathy, restrictive cardiomyopathy |
| Prevention | N/A |
| Treatment | Chemotherapy, heart transplant, supportive care |
| Medication | Tafamidis, doxycycline, diflunisal |
| Prognosis | Variable, depends on type and stage |
| Frequency | Rare |
| Deaths | N/A |



Cardiac Amyloidosis is a medical condition characterized by the abnormal deposition of amyloid proteins in the heart tissue, leading to progressive heart failure. It is a form of systemic amyloidosis and is classified into several types based on the protein involved.
Etiology[edit]
Cardiac amyloidosis is caused by the accumulation of insoluble amyloid fibrils in the extracellular space of the myocardium. These fibrils are derived from different precursor proteins, which determine the type of cardiac amyloidosis. The most common types are:
- AL amyloidosis: Also known as primary amyloidosis, it is caused by light chain proteins produced by abnormal plasma cells.
- ATTR amyloidosis: This type can be hereditary (ATTRm) or non-hereditary (ATTRwt). It is caused by transthyretin, a protein produced by the liver.
Clinical Presentation[edit]
Patients with cardiac amyloidosis may present with symptoms of heart failure, such as dyspnea, fatigue, and edema. Other symptoms can include arrhythmias and syncope. The disease often goes undiagnosed due to its non-specific symptoms and the rarity of the condition.
Diagnosis[edit]
Diagnosis of cardiac amyloidosis involves a combination of clinical assessment, imaging studies, and laboratory tests. Echocardiography and cardiac MRI are commonly used imaging modalities. Definitive diagnosis requires a biopsy of the affected tissue, demonstrating amyloid deposits.
Treatment[edit]
Treatment of cardiac amyloidosis is aimed at reducing the production of the amyloid protein and managing the symptoms of heart failure. This can involve chemotherapy for AL amyloidosis or liver transplantation for ATTRm amyloidosis. Supportive care, including diuretics and antiarrhythmics, is also important.
Prognosis[edit]
The prognosis of cardiac amyloidosis is generally poor, with a median survival of less than a year for untreated AL amyloidosis. However, early detection and treatment can improve survival and quality of life.
See Also[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian